literature

HBV mutation literature information.

Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.

PMID: 29630974 2018 Antiviral research

Abstract: 3.69-fold in half maximal effective concentration of wild-type strain); rtA181T/sW172L + rtS202G + rtM204V strain exhibited higher HBV DNA production and entecavir resistance fold than that of rtA181T/sW172* + rtS202G + rtM204V strain (50.98% vs.

Abstract: 44.33% (524/1182) rtA181T-positive samples were detected with signature drug-resistant mutations,

Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.

PMID: 29654894 2018 International journal of antimicrobial agents

Abstract: Despite >50% of M204I/V+-L180M among all HBV resistance cases annually and extensive exposure of patients to lamivudine (LAM), telbivudine (LdT) and adefovir dipivoxil (ADV), ETV resistance also showed a dramatically increased incidence, which rose to 17.1% in 2016.

[Monitoring by high-sensitivity HBV DNA assay during treatment in chronic hepatitis B e antigen negative patients].

PMID: 29804376 2018 Zhonghua gan zang bing za zhi

Abstract: New mutation sites such as G1915A / C, L180M, M204V, V207I / L, T184A and V173L were detected, Low resistance rate (25%).

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

PMID: 29859062 2018 BMC infectious diseases

Abstract: Strong correlation was observed between sP120T and rtM204I/V (P < 0.001), and their co-presence determined an increased HBV-DNA.

Abstract: The immune-associated escape mutations and the NA-induced immune-escape mutations sI195M, sI196S, and sE164D (resulting from drug-resistance mutation rtM204 V, rtM204I, and rtV173L) were retrieved from literature and examined.

Figure: The NA-induced immune-escape mutations

Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.

PMID: 30075160 2018 Virus research

Abstract: Sequencing reverse transcriptase region of HBV revealed that the patient developed lamivudine-resistant mutations (rtV173 L, rtL180 M, and rtM204 V) 36 months after the start of lamivudine therapy, and lamivudine-resistant mutants reversed to wild-type after the treatment was stopped for 8 months.

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.

PMID: 30080852 2018 PLoS neglected tropical diseases

Abstract: The commonest RAM was rtM204I/V, either alone or in combination with associated mutations, and identified in both reportedly treatment-naive and treatment-experienced adults.

Abstract: We also identified the suite of mutations rtM204V/I + rtL180M + rtV173L, that has been associated with vaccine escape, in over 1/3 of cohorts.

Introduction: Virological breakthrough on TDF therapy has been reported in two patients harbouring rtS78T/sC69 mutations, and in another patient with multi-site polymerase mutations; rt<

Genetic variability in coding regions of the surface antigen and reverse transcriptase domain of hepatitis B virus polymerase, Colombia, 2002-2014

PMID: 30184362 2018 Biomedica

Abstract: The L180M and M204V resistance mutations were simultaneously identified in one sample, while the I169L resistance mutation was identified in another one.

Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.

PMID: 30202825 2018 Hepatology communications

Abstract: HBV harboring the rtA181C substitution without LVDr substitutions rtL180M+rtM204V remained susceptible to inhibition by ETV, adefovir, and tenofovir, although cross-resistance to LVD and telbivudine was observed.

Abstract: One LVD-experienced patient-derived HBV RT harboring LVDr substitutions rtL180M+rtM204V with rtA181C displayed reduced ETV susceptibility (122-fold greater than wild-type HBV) and remained susceptible to adefovir and tenofovir.

Abstract: Previous studies revealed that ETV-resistant (ETVr) HBV DNA re

Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.

PMID: 30586543 2018 The Brazilian journal of infectious diseases

1Abstract: We generated a stable cell line encoding the major pattern of lamivudine-resistant mutations rtL180M/M204V and designated it ""HepG2.RL1""."

Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India.

PMID: 28591184 2017 PloS one

Result: Despite the patient population being ART-naive, one OBI sample (O-EICIS.9; belonging to HBV/A1) of 17 (5.9%) harbored the rtL180M+rtM204V lamivudine resistant mutations.

Table: M204V

Discussion: Furthermore, 3TC resistance mutations (rtL180M + rtM204V) were also observed in one of the OBI patients, despite the population being treatment-naive.

Browser Board

Co-occurred Entities

Filtrator